

Subscribing organizations are encouraged to copy and distribute this table of contents for non-commercial purposes

Focus Topics at BioScience2006

Control of Immune Responses

SECC Glasgow, U.K., 23–27 July 2006

Edited by B. Foxwell (Imperial College London, U.K.), G. Graham (Glasgow, U.K.), R. Nibbs (Glasgow, U.K.) and S. Ward (Bath, U.K.)

| | |
|---|------------------|
| Natural post-translational modifications of chemokines P. Proost, S. Struyf and J. Van Damme | 997–1001 |
| Leucocyte expression of the chemokine scavenger D6 C.S. McKimmie and G.J. Graham | 1002–1004 |
| Throwing light on DARC M. Pruenster and A. Rot | 1005–1008 |
| Chemokine sequestration by atypical chemokine receptors C.A.H. Hansell, C.V. Simpson and R.J.B. Nibbs | 1009–1013 |
| The chemoattractant decoy receptor D6 as a negative regulator of inflammatory responses E.M. Borroni, C. Buracchi, Y. Martinez de la Torre, E. Galliera, A. Vecchi, R. Bonecchi, A. Mantovani and M. Locati | 1014–1017 |
| Dual-specificity phosphatase 1: a critical regulator of innate immune responses S.M. Abraham and A.R. Clark | 1018–1023 |
| Negative regulation of leucocyte functions by CD33-related siglecs T. Avril, H. Attrill, J. Zhang, A. Raper and P.R. Crocker | 1024–1027 |
| STAT3-mediated anti-inflammatory signalling P.J. Murray | 1028–1031 |
| The therapeutic potential of positive and negative immune cell co-stimulation during inflammation E. Gwyer, R. Snelgrove and T. Hussell | 1032–1036 |
| Controlling inflammation: the cholinergic anti-inflammatory pathway V.A. Pavlov and K.J. Tracey | 1037–1040 |
| Protein tyrosine phosphatases as negative regulators of the immune response G.M. Dolton, J.G. Sathish and R.J. Matthews | 1041–1045 |

Molecular Basis of Transcription

SECC Glasgow, U.K., 23–27 July 2006

Edited by S. Busby (Birmingham, U.K.), R. Weinzierl (Imperial College London, U.K.) and R. White (Glasgow, U.K.)

| | |
|---|------------------|
| Perspectives on the RNA polymerase II core promoter T. Juven-Gershon, J.-Y. Hsu and J.T. Kadonaga | 1047–1050 |
|---|------------------|

| | |
|--|------------------|
| Core promoter elements recognized by transcription factor IIB W. Deng and S.G.E. Roberts | 1051–1053 |
| The human androgen receptor AF1 transactivation domain: interactions with transcription factor IIF and molten-globule-like structural characteristics D.N. Lavery and I.J. McEwan | 1054–1057 |
| Recent structural studies of RNA polymerases II and III P. Cramer | 1058–1061 |
| The regulatory roles and mechanism of transcriptional pausing R. Landick | 1062–1066 |
| A second paradigm for gene activation in bacteria M. Buck, D. Bose, P. Burrows, W. Cannon, N. Joly, T. Pape, M. Rappas, J. Schumacher, S. Wigneshweraraj and X. Zhang | 1067–1071 |
| Transcription regulatory circuits in bacterial plasmids C.M. Thomas | 1072–1074 |
| Recruitment of RNA polymerase to Class II CRP-dependent promoters is improved by a second upstream-bound CRP molecule N.S. Miroslavova, J.E. Mitchell, J. Tebbutt and S.J.W. Busby | 1075–1078 |
| A new paradigm for the regulation of the mammalian ribosomal RNA genes T. Moss, V. Stefanovsky, F. Langlois and T. Gagnon-Kugler | 1079–1081 |
| Transcription factor TFIIB and transcription by RNA polymerase III G.A. Kassavetis and E.P. Geiduschek | 1082–1087 |



Nuclear Receptors: Structure, Mechanisms and Therapeutic Targets

SECC Glasgow, U.K., 23–27 July 2006

Edited by C. Bevan (Imperial College London, U.K.), D. Black (Organon, U.K.) and I. McEwan (Aberdeen, U.K.)

| | |
|---|------------------|
| The androgen receptor DNA-binding domain determines androgen selectivity of transcriptional response G. Verrijdt, T. Tanner, U. Moehren, L. Callewaert, A. Haelens and F. Claessens | 1089–1094 |
| Cannabinoids and PPAR α signalling Y. Sun, S.P.H. Alexander, D.A. Kendall and A.J. Bennett | 1095–1097 |
| Structural dynamics of the human androgen receptor: implications for prostate cancer and neurodegenerative disease J. Duff, P. Davies, K. Watt and I.J. McEwan | 1098–1102 |
| The nuclear receptor co-repressor RIP140 controls the expression of metabolic gene networks M.G. Parker, M. Christian and R. White | 1103–1106 |
| Post-translational control of Nur77 A.D. Wingate and J.S.C. Arthur | 1107–1109 |

| | |
|---|------------------|
| Liver X receptors and cholesterol homoeostasis: spotlight on the adrenal gland C.L. Cummins and D.J. Mangelsdorf | 1110-1113 |
| New developments in oestrogen signalling in colonic epithelium O. Wada-Hiraike, M. Warner and J.-Å. Gustafsson | 1114-1116 |
| Patterns of exposure to glucocorticoid receptor ligand S.L. Lightman | 1117-1118 |
| The impact of pregnane X receptor activation on liver fibrosis M.C. Wright | 1119-1123 |
| Mechanisms of androgen receptor repression in prostate cancer S.M. Powell, G.N. Brooke, H.C. Whitaker, V. Reebye, S.C. Gamble, D. Chotai, D.A. Dart, B. Belandia and C.L. Bevan | 1124-1127 |
| Transcriptional regulation of macrophage cholesterol trafficking by PPAR α and LXR G. Chinetti, J.C. Fruchart and B. Staels | 1128-1131 |

Mechanisms of Gene Regulation

SECC Glasgow, U.K., 23–27 July 2006

Edited by S. Graham (Glasgow, U.K.)

Sponsored by Pfizer

| | |
|---|------------------|
| Transcription factories: structures conserved during differentiation and evolution I. Faro-Trindade and P.R. Cook | 1133-1137 |
| Multiple chromatin modifications important for gene expression changes in cardiac hypertrophy A.J. Bingham, L. Ooi and I.C. Wood | 1138-1140 |
| Transforming growth factor- β -regulated expression of genes in macrophages implicated in the control of cholesterol homoeostasis D.P. Ramji, N.N. Singh, P. Foka, S.A. Irvine and K. Arnaoutakis | 1141-1144 |
| Regulation of splicing-associated SR proteins by HPV-16 S. Mole, T. Veerapraditsin, M.G. McPhillips and S.V. Graham | 1145-1147 |
| Does everything now make (anti)sense? J.A. Timmons and L. Good | 1148-1150 |

Preparing for the Pandemic: Universities and Public Health

SECC Glasgow, U.K., 23–27 July 2006

Edited by K. Gartland (Glasgow Caledonian, U.K.)

| | |
|---|------------------|
| Confronting an influenza pandemic: ethical and scientific issues U. Schuklenk and K.M.A. Gartland | 1151-1154 |
| The transmissible spongiform encephalopathies: emerging and declining epidemics J.C. Manson, E. Cancellotti, P. Hart, M.T. Bishop and R.M. Barron | 1155-1158 |

Independent Meetings

8th International Symposium on Cytochrome P450 Biodiversity and Biotechnology

Swansea Medical School, Swansea, Wales, U.K., 23–27 July 2006

Edited by **D. Kelly, D. Lamb and S. Kelly (Swansea, U.K.)**

| | |
|---|------------------|
| Cytochrome P450 biodiversity and biotechnology S.L. Kelly, D.C. Lamb and D.E. Kelly | 1159–1160 |
| Biodiversity of CYP51 in trypanosomes G.I. Lepesheva, T.Y. Hargrove, R.D. Ott, W.D. Nes and M.R. Waterman | 1161–1164 |
| P450ome of the white rot fungus <i>Phanerochaete chrysosporium</i> : structure, evolution and regulation of expression of genomic P450 clusters J.S. Yadav, H. Doddapaneni and V. Subramanian | 1165–1169 |
| Protein dynamics and imidazole binding in cytochrome P450 enzymes A. Verras and P.R. Ortiz de Montellano | 1170–1172 |
| Flavocytochrome P450 BM3 and the origin of CYP102 fusion species H.M. Girvan, T.N. Waltham, R. Neeli, H.F. Collins, K.J. McLean, N.S. Scrutton, D. Leys and A.W. Munro | 1173–1177 |
| CYP121, CYP51 and associated redox systems in <i>Mycobacterium tuberculosis</i> : towards deconvoluting enzymology of P450 systems in a human pathogen K.J. McLean, A.J. Dunford, M. Sabri, R. Neeli, H.M. Girvan, P.R. Balding, D. Leys, H.E. Seward, K.R. Marshall and A.W. Munro | 1178–1182 |
| Understanding electron transport systems of <i>Streptomyces</i> cytochrome P450 Y.-J. Chun, T. Shimada, M.R. Waterman and F.P. Guengerich | 1183–1185 |
| Biochemical analysis of mutations in P450 oxidoreductase A.V. Pandey | 1186–1191 |
| Functional annotation of the <i>Arabidopsis</i> P450 superfamily based on large-scale co-expression analysis J. Ehltling, N.J. Provart and D. Werck-Reichhart | 1192–1198 |
| Dwarfism and cytochrome P450-mediated C-6 oxidation of plant steroid hormones G. Bishop, T. Nomura, T. Yokota, T. Montoya, J. Castle, K. Harrison, T. Kushiro, Y. Kamiya, S. Yamaguchi, S. Bancos, A.-M. Szatmári and M. Szekeres | 1199–1201 |
| Cytochrome P450 subfamily CYP710A genes encode sterol C-22 desaturase in plants T. Morikawa, M. Mizutani and D. Ohta | 1202–1205 |
| The role of cytochrome P450 enzymes in the biosynthesis of camalexin E. Glawischnig | 1206–1208 |
| Cytochrome P450 mono-oxygenases in conifer genomes: discovery of members of the terpenoid oxygenase superfamily in spruce and pine B. Hamberger and J. Bohlmann | 1209–1214 |

| | |
|---|-----------|
| Function and engineering of the 15 β -hydroxylase CYP106A2 C. Virus, M. Lisurek, B. Simgen, F. Hannemann and R. Bernhardt | 1215–1218 |
| Impact of changes in the target P450 CYP51 enzyme associated with altered triazole-sensitivity in fungal pathogens of cereal crops H.J. Cools, B.A. Fraaije, S.H. Kim and J.A. Lucas | 1219–1222 |
| CYP74C3 and CYP74A1, plant cytochrome P450 enzymes whose activity is regulated by detergent micelle association, and proposed new rules for the classification of CYP74 enzymes R.K. Hughes, E.J. Belfield and R. Casey | 1223–1227 |
| The involvement of cytochrome P450 system in the fate of 2,4,6-trinitrotoluene (TNT) in European eel [<i>Anguilla anguilla</i> (Linnaeus, 1758)] C. Della Torre, I. Corsi, L. Alcaro, E. Amato and S. Focardi | 1228–1230 |
| Towards engineered topogenesis of cytochrome <i>b</i> ₅ and P450 for <i>in vivo</i> transformation of xenobiotics M.A. Kaderbhai, S.L. Kelly and N.N. Kaderbhai | 1231–1235 |
| Biocatalytic conversion of avermectin into 4''-oxo-avermectin: discovery, characterization, heterologous expression and specificity improvement of the cytochrome P450 enzyme I. Molnár, V. Jungmann, J. Stege, A. Trefzer and J.P. Pachlatko | 1236–1240 |
| Oxidative metabolic profiling of xenobiotics by human P450s expressed in tobacco cell suspension cultures B. Schmidt, N. Jousen, M. Bode and I. Schuphan | 1241–1245 |
| Proteomic analysis of cytochromes P450: a mass spectrometry approach Y. Wang, A. Al-Gazzar, C. Seibert, A. Sharif, C. Lane and W.J. Griffiths | 1246–1251 |
| Evolution of insect P450 R. Feyereisen | 1252–1255 |
| The Halloween genes code for cytochrome P450 enzymes mediating synthesis of the insect moulting hormone K.F. Rewitz, R. Rybczynski, J.T. Warren and L.I. Gilbert | 1256–1260 |

International Symposium on Neurodegeneration and Neuroprotection

University of Münster, Germany, 23–26 July 2006

Edited by S. Klumpp and J. Kriegstein (Münster, Germany)

| | |
|--|-----------|
| Vascular matrix adhesion and the blood–brain barrier G.J. del Zoppo, R. Milner, T. Mabuchi, S. Hung, X. Wang and J.A. Koziol | 1261–1266 |
| Signalling pathways mediating inflammatory responses in brain ischaemia A.M. Planas, R. Gorina and Á. Chamorro | 1267–1270 |
| Perspectives on neuroprotective stroke therapy W.-R. Schäbitz and M. Fisher | 1271–1276 |
| Survival signalling in Alzheimer's disease W.J. Lukiw and N.G. Bazan | 1277–1282 |

| | |
|---|-----------|
| Mitochondrial translocation of p53 underlies the selective death of hippocampal CA1 neurons after global cerebral ischaemia H. Endo, A. Saito and P.H. Chan | 1283–1286 |
| Signalling molecules essential for neuronal survival and differentiation K. Frebel and S. Wiese | 1287–1290 |
| NF- κ B signalling in cerebral ischaemia M. Schwaninger, I. Inta and O. Herrmann | 1291–1294 |
| Insights into cytoprotection from ground squirrel hibernation, a natural model of tolerance to profound brain oligoemia Y.-J. Lee and J.M. Hallenbeck | 1295–1298 |
| Control of neuronal excitability by phosphorylation and dephosphorylation of sodium channels T. Scheuer and W.A. Catterall | 1299–1302 |
| Protein kinase CK2: a newcomer in the ‘druggable kinome’ M.A. Pagano, L. Cesaro, F. Meggio and L.A. Pinna | 1303–1306 |
| Mining for survival genes V.L. Dawson and T.M. Dawson | 1307–1309 |
| Neuroprotection and neurosupplementation in ischaemic brain T. Yamashita, K. Deguchi, K. Sawamoto, H. Okano, T. Kamiya and K. Abe | 1310–1312 |
| Blood genomic profiling: novel diagnostic and therapeutic strategies for stroke? A.E. Baird | 1313–1317 |
| Translational vehicles for neuroprotection M. Papadakis and A.M. Buchan | 1318–1322 |
| The ALIAS (ALbumin In Acute Stroke) Phase III randomized multicentre clinical trial: design and progress report M.D. Ginsberg, Y.Y. Palesch and M.D. Hill for the ALIAS Trialists | 1323–1326 |
| G-CSF and neuroprotection: a therapeutic perspective in cerebral ischaemia C.-Z. Lu and B.-G. Xiao | 1327–1333 |
| Targeting Bid to prevent programmed cell death in neurons C. Culmsee and N. Plesnila | 1334–1340 |
| PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases R. Bordet, T. Ouk, O. Petrault, P. Gelé, S. Gautier, M. Laprais, D. Deplanque, P. Duriez, B. Staels, J.C. Fruchart and M. Bastide | 1341–1346 |
| Mitochondrial pathways of neuronal necrosis J. Niquet, D.-W. Seo and C.G. Wasterlain | 1347–1351 |
| Toll-like receptors and tolerance to ischaemic injury in the brain S.L. Stevens and M.P. Stenzel-Poore | 1352–1355 |
| Acidotoxicity in brain ischaemia R. Simon and Z. Xiong | 1356–1361 |

| | |
|---|------------------|
| Oestrogen and stroke: the potential for harm as well as benefit I.M. Macrae and H.V. Carswell | 1362–1365 |
| A new approach for the investigation of reperfusion-related brain injury C.M. Maier, L. Hsieh, T. Crandall, P. Narasimhan and P.H. Chan | 1366–1369 |
| Protein phosphatases types 2C α and 2C β in apoptosis S. Klumpp, M.-C. Thissen and J. Krieglstein | 1370–1375 |